Eckert & Ziegler increases profit forecast for financial year 2017
Insider information pursuant to Article 17 MAREckert & Ziegler increases profit forecast for financial year 2017
Berlin, 25 July 2017 - Eckert & Ziegler AG (ISIN DE 0005659700) increases its full year profit forecast for the financial year 2017, on the basis of preliminary, unaudited figures for the second quarter 2017. Due to one-off effects resulting from the sale of the cyclotron division in May 2017 the Executive Board expects a profit per share of approximately 2.80 EUR, thereof 0.60 EUR resulting from one-off effects and discontinued operations. Sales of just under EUR 150 million are expected.
The complete figures for the first half year 2017 will be published on 2 August 2017.
Your contact: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, 13125 Berlin Tel.: +49 (0) 30 / 94 10 84-138, email@example.com, www.ezag.com
Information and Explanation of the Issuer to this News:About Eckert & Ziegler With around 760 employees, Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is one of the world's largest providers of isotope components for radiation therapy and nuclear medicine.Contributing to saving lives.
25-Jul-2017 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin
Germany Phone: 49 30 941084-138 Fax: 49 30 941084-112 E-mail: firstname.lastname@example.org Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of Announcement DGAP News Service
595427 25-Jul-2017 CET/CEST